Microsoft hasn’t said when Windows 10 Mobile will be released, but today it announced which Lumia devices will get it first.
THIS BLOG IS NOT FOR ADULT OR PORN SITE. WE LOVE TO BLOGGING AND SHARE ARTICLES OR INFORMATION ALL ABOUT HEALTH NEWS, TECHNOLOGY, ENTERTAINMENT, AND BUSINESS. THANKS FOR COMING AND HAPPY READING............
Wednesday, August 5, 2015
Tuesday, July 21, 2015
Citigroup Rating Update on Morgan Stanley (NYSE:MS)
- alibaba -
Brokerage firm Citigroup maintains its rating on Morgan Stanley (NYSE:MS). As per the information, the brokerage house raises the price target to $39 per share from a prior target of $37. The shares have been rated Neutral. The rating by the firm was issued on July 13, 2015.
Sunday, July 5, 2015
POPULAR SUNBURN ART CAN LEAD CANCER
Dermatologists are currently warning the populace against a new trend in skin decoration called sunburn art. Doctors report that this new trend is dangerous because as a form of sunburn it increases the risk of melanoma which is the most common kind of skin cancer in the United States.
Friday, June 26, 2015
Alibaba launches online bank aimed at SMBs, rural customers
China's first online-only banking service provider is using big data technology to grant loans to SMBs and rural customers.
After almost nine months of preparation, e-commerce giant Alibaba has revealed the latest addition to its online financial services network by officially launching the Zhejiang Wangshang Bank.
Wednesday, June 24, 2015
Keryx Announces Two National Insurance Providers Added Auryxia (TM) to Their Medicare Part D Formularies
BOSTON, Jun 24, 2015 (GLOBE NEWSWIRE via COMTEX) -- Keryx Biopharmaceuticals, Inc. KERX, +0.63% a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced that two national insurance providers have added Auryxia™ to their Medicare Part D formularies. Auryxia is the first and only absorbable, iron-based phosphate binder for the treatment of elevated serum phosphorus levels in people with chronic kidney disease on dialysis. Together, these new formularies will increase unrestricted access to Auryxia, across Medicare Part D and commercial insurance providers, to approximately 65 percent of people in the U.S. currently taking phosphate binders.